FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2024
0mins
Source: Benzinga
FDA Approval of Updated COVID-19 Vaccines: The FDA is expected to approve updated mRNA vaccines from Moderna and Pfizer to combat recent COVID-19 strains, particularly KP.2, amid a significant summer outbreak in the U.S. Novovax's vaccine for the JN.1 strain may not receive approval simultaneously.
Current COVID-19 Situation in the U.S.: COVID-19 infections are rising in 25 states, with wastewater data indicating very high levels of the virus. The KP.3.1.1 strain has become prevalent, accounting for 37% of cases recently, as experts attribute the surge to waning immunity and new variants.
Analyst Views on LGHT
Wall Street analysts forecast LGHT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGHT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 10.268
Low
Averages
High
Current: 10.268
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
